Black Rock Inc. Arcellx, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Arcellx, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,516,364 shares of ACLX stock, worth $343 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,516,364

Previous 3,066,068 14.69%

Holding current value

$343 Million

Previous $213 Million 8.99%

% of portfolio

0.0%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$49.74 - $66.98 $22.4 Million - $30.2 Million	450,296 Added 14.69%	3,516,364 $194 Million
Q1 2024 May 10, 2024	BUY	$51.85 - $73.49 $2.46 Million - $3.49 Million	47,530 Added 1.57%	3,066,068 $213 Million
Q4 2023 Feb 13, 2024	BUY	$31.75 - $57.99 $9.87 Million - $18 Million	310,876 Added 11.48%	3,018,538 $168 Million
Q3 2023 Nov 13, 2023	BUY	$31.51 - $37.4 $3.31 Million - $3.93 Million	105,177 Added 4.04%	2,707,662 $97.2 Million
Q2 2023 Aug 11, 2023	BUY	$27.49 - $46.9 $10.4 Million - $17.8 Million	380,128 Added 17.1%	2,602,485 $82.3 Million
Q1 2023 May 12, 2023	BUY	$26.92 - $33.94 $408,591 - $515,141	15,178 Added 0.69%	2,222,357 $68.5 Million
Q4 2022 Feb 13, 2023	BUY	$17.18 - $33.0 $6.89 Million - $13.2 Million	401,076 Added 22.21%	2,207,179 $68.4 Million
Q3 2022 Nov 14, 2022	BUY	$16.67 - $22.04 $20.1 Million - $26.5 Million	1,203,592 Added 199.76%	1,806,103 $33.9 Million
Q2 2022 Aug 12, 2022	BUY	$7.21 - $24.43 $738,347 - $2.5 Million	102,406 Added 20.48%	602,511 $10.9 Million
Q1 2022 May 12, 2022	BUY	$12.97 - $19.14 $6.49 Million - $9.57 Million	500,105 New	500,105 $7.01 Million

Others Institutions Holding ACLX

# of Institutions

179

Shares Held

45.9M

Call Options Held

53.6K

Put Options Held

53.7K

View Full List

About Arcellx, Inc.

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $4.27B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

More about ACLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account